While Beovu has failed to make much of a commercial impact since its launch for wet age-related macular degeneration (AMD), due in the main to safety concerns, Novartis AG is hoping to breathe new life into the eye drug after securing EU approval for a second indication, diabetic macular edema.
Novartis Hopes Eye Drug Beovu Bounces Back After New Approval
Gets EU Okay For Diabetic Macular Edema
Having struggled to allay safety concerns for its use in wet age-related macular degeneration, the Swiss major has faith Beovu's efficacy and less frequent dosing will prove more than a match for established DME rival Eylea and newcomer Vabysmo.
